EVERY DISEASE HAS ITS OWN MEDICINE *
We have developed a new therapy that has been proven to be helpful for patients with arteriosclerosis. This therapy will be available to patients in the near future. The newly developed drug is a special enzyme mixture that will be highly effective in our BelACT therapy.
* Paracelsus 1493-1541 – (Philippus Aureolus Theophrastus Bombastus von Hohenheim)
THERAPY FOR ARTHERIOCLEROSIS
The BelACT therapy is used for the treatment of arteriosclerosis, a disease that becomes more and more evident with the age. Arteriosclerosis describes a change in the blood vessels that is responsible for a large number of cardiovascular diseases and is therefore one of the main causes of premature death.
Arteriosclerosis is characterized by an increasing stiffness of the entire vascular wall and the formation of atherosclerotic plaques on the inner walls of the arteries.
One of the causes is lipid and calcium accumulation, increasing inflammation and loss of connective tissue elasticity is upcoming. This can lead to permanently increased blood pressure and, with increasing plaque formation, to a narrowing of the arterial flow path.
NEW PHARMACEUTICAL PRODUCT
The production of the medicament used to treat arteriosclerosis will be located in Berlin. The essential steps are in preparation. The first batch of the drug for the treatment of arteriosclerosis is expected in the fourth quarter of 2019.
Parallel to the pharmaceutical production, we work on the required steps for the approval of the active substance (toxicology and clinical studies) and the relevant tasks for the approval by the European Medicines Agency (EMA).